이 애플리케이션의 일부 콘텐츠는 현재 사용할 수 없습니다.
이 상황이 계속되면 다음 주소로 문의하십시오피드백 및 연락
1. (WO2017148879) OBINUTUZUMAB AND RITUXIMAB VARIANTS HAVING REDUCED ADCP
국제사무국에 기록된 최신 서지정보    정보 제출

공개번호: WO/2017/148879 국제출원번호: PCT/EP2017/054542
공개일: 08.09.2017 국제출원일: 28.02.2017
IPC:
C07K 16/28 (2006.01) ,A61K 39/00 (2006.01)
C SECTION C — 화학; 야금
07
유기화학
K
펩티드 (Peptides)
16
면역글로불린(Immunoglobulins), 예. 모노클로날(monoclonal) 또는 폴리클로날 항체(polyclonal antibodies)
18
.동물 또는 인체로부터 유도된 물질인 것
28
수용체(receptors), 세포표면 항원 또는 세포표면 결정인자에 관한 것
A SECTION A — 생활필수품 농업
61
위생학; 의학 또는 수의학
K
의약용, 치과용 또는 화장용 제제
39
항원 또는 항체를 함유한 의료품 제제
출원인:
F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 4070 Basel, CH (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JP, KE, KG, KH, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department Little Falls, NJ 07424, US (US)
발명자:
BRUENKER, Peter; CH
HERTING, Frank; DE
HERTER, Sylvia; CH
KLEIN, Christian; CH
MOESSNER, Ekkehard; CH
SCHLOTHAUER, Tilman; DE
대리인:
BRODBECK, Michel; CH
우선권 정보:
16158083.201.03.2016EP
16198788.815.11.2016EP
발명의 명칭: (EN) OBINUTUZUMAB AND RITUXIMAB VARIANTS HAVING REDUCED ADCP
(FR) VARIANTS DE L'OBINUTUZUMAB ET DU RITUXIMAB LIÉS À UNE MOINDRE PHAGOCYTOSE DÉPENDANTE DES ANTICORPS (ADCP)
요약서:
(EN) The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having reduced effector function and altered ability to mediate cell signaling activity by a target antigen. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.
(FR) La présente invention concerne des anticorps modifiés. En particulier, la présente invention concerne des anticorps monoclonaux recombinants ou leurs fragments, y compris des anticorps ou fragments chimériques, primatisés ou humanisés, présentant une diminution de leur fonction effectrice et une altération de leur capacité à induire l'activité de signalisation cellulaire via un antigène cible. De plus, la présente invention concerne des molécules d'acide nucléique codant pour ces anticorps, ainsi que des vecteurs et des cellules hôtes comprenant ces molécules d'acide nucléique. L'invention concerne par ailleurs des méthodes pour produire les anticorps de l'invention, et des méthodes pour utiliser ces anticorps dans le traitement de maladies.
지정국: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
아프리카지역 지식재산권기구(ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
유라시아 특허청 (AM, AZ, BY, KG, KZ, RU, TJ, TM)
유럽 특허청(EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
공개언어: 영어 (EN)
출원언어: 영어 (EN)